Communiqués Novavax, Inc.

Actions

NVAX

US6700024010

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 18:51:31 09/09/2026			Varia. 5j.	Varia. 1 janv.
9,815 ^USD	-3,68%		-4,94%	+45,98%

28/08	Novavax, Inc., Sanofi S.A. et Takeda Pharmaceutical Company Limited reçoivent les approvations pour la formulation de Nuvaxovid adaptée au variant XFG aux États-Unis, dans l'Union européenne et au Japon pour la saison vaccinale 2026-2027	CI
28/08	Le Nuvaxovid de Novavax approuvé aux États-Unis, dans l'UE et au Japon pour la saison 2026-2027	MT

Communiqués

31/08	Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season	AQ
28/08	Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season	PR
06/08	Novavax: Q2 Earnings Snapshot	AQ
06/08	Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights	PR
30/07	Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026	PR
01/06	Novavax to Participate in 2026 Jefferies Global Healthcare Conference	PR
07/05	Novavax to Participate in BofA Securities 2026 Health Care Conference	PR
06/05	Novavax : Q1 Reports & Financials (nvax q1 2026 earnings presentation)	PU
06/05	Novavax: Q1 Earnings Snapshot	AQ
06/05	Novavax Reports First Quarter 2026 Financial Results and Operational Highlights	PR
29/04	Novavax to Report First Quarter 2026 Financial Results on May 6, 2026	PR
18/04	Novavax : Nuvaxovid™ COVID-19 Vaccine Showed Better Tolerability than mNEXSPIKE in Head-to-head Sanofi-led Phase 4 Study	PU
30/03	Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development	PR
26/02	Novavax to Participate in Upcoming Investor Conferences	PR
26/02	Novavax: Q4 Earnings Snapshot	AQ
26/02	Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights	PR
19/02	Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026	PR
20/01	Novavax Announces Entering into a License Agreement with Pfizer	PR
07/01	Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference	PR
12/11	Novavax to Participate in Jefferies London Healthcare Conference	PR
06/11	Novavax : Q3 Reports & Financials (nvax q3 25 earnings presentation)	PU
06/11	Novavax: Q3 Earnings Snapshot	AQ
06/11	Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights	PR
04/11	Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment	PR
30/10/25	Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025	PR